{"title":"Denosumab和泼尼松治疗的不典型股骨骨折伴多发性椎体压缩性骨折、虚弱和生活质量下降","authors":"Gayle Frazzetta MD, FAAFP","doi":"10.1016/j.jocd.2023.101390","DOIUrl":null,"url":null,"abstract":"<div><h3>Case Description</h3><p>Atypical Femur Fracture<span><span><span> on Denosumab and </span>Prednisone<span><span><span> with Multiple Vertebral Compression Fractures, </span>Frailty, and Diminishing </span>Quality of Life CO is a 70yo female with end-stage O2 and steroid dependent COPD/asthma with multiple thoracic and lumbar compression fractures contributing/causing non-ambulatory status and impairment of ADL's. She was treated with denosumab(Prolia) 2011-2015 until atypical femur fracture (figure 1) and </span></span>metatarsal fracture occurred. She was on risedronate(Actonel) prior to this, 2004-2007, until side effects of esophageal spasm/GI irritation occurred and therapy was discontinued. Teriparatide(Forteo) was offered after discontinuing denosumab however patient noted possibility of bone cancer and declined it.</span></p><p><span><span>Compression fracture bracing and walker to wheelchair transition occurred about 2 months prior to referral for treatment<span><span> recommendations. PMH: osteoporosis, COPD, asthma, </span>osteoarthritis<span><span>, low back pain with scoliosis and </span>kyphosis, hypertension, previous smoker-quit 2010 (+/-25 pack year hx), </span></span></span>hypokalemia<span><span><span>, ocular migraines PSH: femur repair, cataracts, </span>tubal ligation Meds: </span>lisinopril<span><span> 40mg, prednisone 10mg alternating with 5mg qd, tiotropium inhaled, montelukast 10mg, </span>symbicort<span><span><span> 160/4.5 2 puffs bid, albuterol </span>prn (uses daily), ipratropium/alb </span>nebs<span> bid prn, potassium chloride 20meq qd, </span></span></span></span></span>fluticasone<span><span><span> NS qHS, cetirizine<span> 10mg bid, cyclobenzaprine 5mg prn, acetaminophen prn Supplements: </span></span>multivitamin, glucosamine/chondroitin qd, Vit D 2000IU qd, Ca citrate/D 315-200 qd FamHX: mother: breast cancer & OP Social Hx: married, retired piano instructor, rare alcohol, attends pulmonary rehab 2x/week until recent compression fracture, now unable due to pain </span>ROS<span><span>: unintended weight loss, prednisone dependent x 10 years; unable to tolerate multiple attempts at prednisone taper, significant pain reported from new compression fracture with mobility impairment Imaging Studies XRays: Thoracic spine (2 months prior to eval)1. Scoliosis 2. Multilevel age- indeterminate compression fractures, T10-12. Estimated 50% </span>vertebral body height loss, no change. Mild, anterior compression deformity L1, stable compared to 2018. 2 week follow-up X-ray to above:</span></span></p><p><span><span>1. New mild anterior compression deformity of L2 with approximately 15% vertebral height loss. 2. Unchanged T10-L1 compression fractures. 4mm anterolisthesis of L4 on L5 without change. DXA: recent; Hip T score, total -3.5, </span>femoral neck -4.1, Spine (L1-4) T score -3.0 Comparison to study done 5 years prior: Hip: loss of 16.3%, spine: stable Labs: (Pertinent) </span>Vitamin D<span><span> 35, CBC: WBC 11.7, Hgb 14.2, platelets 324, CMP: n'l, Alk phos: n'l, Ca 9.9, TSH n'l PE: Height; original 4’ 8.5” current 4’ 5.5”, weight 88#, BMI 21, 02: 90% on 3 liters Alert, spry, cognition intact, in wheelchair, labored breathing, prominent thoracic kyphosis, back brace in place. Patient request to “heal </span>vertebrae and have ability to walk without a walker and back brace.” A treatment dilemma given history of atypical femur fracture while on denosumab and prednisone and continued progression/worsening of compression fractures, frailty and diminishing quality of life.</span></p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Atypical Femur Fracture on Denosumab and Prednisone with Multiple Vertebral Compression Fractures, Frailty and Diminishing Quality of Life\",\"authors\":\"Gayle Frazzetta MD, FAAFP\",\"doi\":\"10.1016/j.jocd.2023.101390\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Case Description</h3><p>Atypical Femur Fracture<span><span><span> on Denosumab and </span>Prednisone<span><span><span> with Multiple Vertebral Compression Fractures, </span>Frailty, and Diminishing </span>Quality of Life CO is a 70yo female with end-stage O2 and steroid dependent COPD/asthma with multiple thoracic and lumbar compression fractures contributing/causing non-ambulatory status and impairment of ADL's. She was treated with denosumab(Prolia) 2011-2015 until atypical femur fracture (figure 1) and </span></span>metatarsal fracture occurred. She was on risedronate(Actonel) prior to this, 2004-2007, until side effects of esophageal spasm/GI irritation occurred and therapy was discontinued. Teriparatide(Forteo) was offered after discontinuing denosumab however patient noted possibility of bone cancer and declined it.</span></p><p><span><span>Compression fracture bracing and walker to wheelchair transition occurred about 2 months prior to referral for treatment<span><span> recommendations. PMH: osteoporosis, COPD, asthma, </span>osteoarthritis<span><span>, low back pain with scoliosis and </span>kyphosis, hypertension, previous smoker-quit 2010 (+/-25 pack year hx), </span></span></span>hypokalemia<span><span><span>, ocular migraines PSH: femur repair, cataracts, </span>tubal ligation Meds: </span>lisinopril<span><span> 40mg, prednisone 10mg alternating with 5mg qd, tiotropium inhaled, montelukast 10mg, </span>symbicort<span><span><span> 160/4.5 2 puffs bid, albuterol </span>prn (uses daily), ipratropium/alb </span>nebs<span> bid prn, potassium chloride 20meq qd, </span></span></span></span></span>fluticasone<span><span><span> NS qHS, cetirizine<span> 10mg bid, cyclobenzaprine 5mg prn, acetaminophen prn Supplements: </span></span>multivitamin, glucosamine/chondroitin qd, Vit D 2000IU qd, Ca citrate/D 315-200 qd FamHX: mother: breast cancer & OP Social Hx: married, retired piano instructor, rare alcohol, attends pulmonary rehab 2x/week until recent compression fracture, now unable due to pain </span>ROS<span><span>: unintended weight loss, prednisone dependent x 10 years; unable to tolerate multiple attempts at prednisone taper, significant pain reported from new compression fracture with mobility impairment Imaging Studies XRays: Thoracic spine (2 months prior to eval)1. Scoliosis 2. Multilevel age- indeterminate compression fractures, T10-12. Estimated 50% </span>vertebral body height loss, no change. Mild, anterior compression deformity L1, stable compared to 2018. 2 week follow-up X-ray to above:</span></span></p><p><span><span>1. New mild anterior compression deformity of L2 with approximately 15% vertebral height loss. 2. Unchanged T10-L1 compression fractures. 4mm anterolisthesis of L4 on L5 without change. DXA: recent; Hip T score, total -3.5, </span>femoral neck -4.1, Spine (L1-4) T score -3.0 Comparison to study done 5 years prior: Hip: loss of 16.3%, spine: stable Labs: (Pertinent) </span>Vitamin D<span><span> 35, CBC: WBC 11.7, Hgb 14.2, platelets 324, CMP: n'l, Alk phos: n'l, Ca 9.9, TSH n'l PE: Height; original 4’ 8.5” current 4’ 5.5”, weight 88#, BMI 21, 02: 90% on 3 liters Alert, spry, cognition intact, in wheelchair, labored breathing, prominent thoracic kyphosis, back brace in place. Patient request to “heal </span>vertebrae and have ability to walk without a walker and back brace.” A treatment dilemma given history of atypical femur fracture while on denosumab and prednisone and continued progression/worsening of compression fractures, frailty and diminishing quality of life.</span></p></div>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094695023000409\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094695023000409","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Atypical Femur Fracture on Denosumab and Prednisone with Multiple Vertebral Compression Fractures, Frailty and Diminishing Quality of Life
Case Description
Atypical Femur Fracture on Denosumab and Prednisone with Multiple Vertebral Compression Fractures, Frailty, and Diminishing Quality of Life CO is a 70yo female with end-stage O2 and steroid dependent COPD/asthma with multiple thoracic and lumbar compression fractures contributing/causing non-ambulatory status and impairment of ADL's. She was treated with denosumab(Prolia) 2011-2015 until atypical femur fracture (figure 1) and metatarsal fracture occurred. She was on risedronate(Actonel) prior to this, 2004-2007, until side effects of esophageal spasm/GI irritation occurred and therapy was discontinued. Teriparatide(Forteo) was offered after discontinuing denosumab however patient noted possibility of bone cancer and declined it.
Compression fracture bracing and walker to wheelchair transition occurred about 2 months prior to referral for treatment recommendations. PMH: osteoporosis, COPD, asthma, osteoarthritis, low back pain with scoliosis and kyphosis, hypertension, previous smoker-quit 2010 (+/-25 pack year hx), hypokalemia, ocular migraines PSH: femur repair, cataracts, tubal ligation Meds: lisinopril 40mg, prednisone 10mg alternating with 5mg qd, tiotropium inhaled, montelukast 10mg, symbicort 160/4.5 2 puffs bid, albuterol prn (uses daily), ipratropium/alb nebs bid prn, potassium chloride 20meq qd, fluticasone NS qHS, cetirizine 10mg bid, cyclobenzaprine 5mg prn, acetaminophen prn Supplements: multivitamin, glucosamine/chondroitin qd, Vit D 2000IU qd, Ca citrate/D 315-200 qd FamHX: mother: breast cancer & OP Social Hx: married, retired piano instructor, rare alcohol, attends pulmonary rehab 2x/week until recent compression fracture, now unable due to pain ROS: unintended weight loss, prednisone dependent x 10 years; unable to tolerate multiple attempts at prednisone taper, significant pain reported from new compression fracture with mobility impairment Imaging Studies XRays: Thoracic spine (2 months prior to eval)1. Scoliosis 2. Multilevel age- indeterminate compression fractures, T10-12. Estimated 50% vertebral body height loss, no change. Mild, anterior compression deformity L1, stable compared to 2018. 2 week follow-up X-ray to above:
1. New mild anterior compression deformity of L2 with approximately 15% vertebral height loss. 2. Unchanged T10-L1 compression fractures. 4mm anterolisthesis of L4 on L5 without change. DXA: recent; Hip T score, total -3.5, femoral neck -4.1, Spine (L1-4) T score -3.0 Comparison to study done 5 years prior: Hip: loss of 16.3%, spine: stable Labs: (Pertinent) Vitamin D 35, CBC: WBC 11.7, Hgb 14.2, platelets 324, CMP: n'l, Alk phos: n'l, Ca 9.9, TSH n'l PE: Height; original 4’ 8.5” current 4’ 5.5”, weight 88#, BMI 21, 02: 90% on 3 liters Alert, spry, cognition intact, in wheelchair, labored breathing, prominent thoracic kyphosis, back brace in place. Patient request to “heal vertebrae and have ability to walk without a walker and back brace.” A treatment dilemma given history of atypical femur fracture while on denosumab and prednisone and continued progression/worsening of compression fractures, frailty and diminishing quality of life.
期刊介绍:
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.